Upregulation of Neural Cell Adhesion Molecule 1 (NCAM1) by hsa-miR-141-3p Suppresses Ameloblastoma Cell Migration

Background: Neural cell adhesion molecule 1 (NCAM1; CD56) and E-cadherin are both involved in cell-cell adhesion and cell development processes, and their dysregulation is associated with various tumors. We hypothesized that dysregulated NCAM1 could suppress the invasive behavior of ameloblastoma (AB), and its expression was regulated by miR-141-3p.

Material/Methods: Real-time qPCR was performed to examine differences in miR-141-3p expression between AB tissues and normal oral tissues (NOMs). The potential target NCAM1 of miR-141-3p was predicted by bioinformatics analysis, which was validated through dual-luciferase assay. The mRNA and protein levels of NCAM1 were detected by real-time qPCR and Western blot, respectively. Furthermore, the expression and distribution of NCAM1 in AB were investigated through immunohistochemical staining, and immunohistochemical staining of E-cadherin was also performed. After overexpression of NCAM1, the migration of AM-1 cells was examined using wound-healing assay.

Results: Real-time qPCR results confirmed that miR-141-3p was significantly downregulated in AB tissues. According to bioinformatics analysis, NCAM1 was a target of miR-141-3p, which was confirmed by dual luciferase assay. We found that NCAM1 was significantly upregulated in AB tissues at the mRNA and protein levels. Furthermore, NCAM1 and E-cadherin were mainly expressed on the cell membrane of AB. Downregulation of E-cadherin was found in AB tissues. As shown in wound-healing assay results, NCAM1 overexpression significantly inhibited the invasiveness of AM-1 cells.

Conclusions: In this study, highly expressed NCAM1 was found in AB, and it suppressed the migration of AB cells and was regulated by miR-141-3p, suggesting its potential value as a therapeutic target for AB.

MeSH Keywords: Ameloblastoma • Cell Migration Assays • MicroRNAs • Neural Cell Adhesion Molecules

Abbreviations: AB – ameloblastoma; NCAM1 – neural cell adhesion molecule 1; miRNA – microRNA; NOM – normal oral mucosa; EMT – epithelial-mesenchymal transition

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/923491
AB is a common benign odontogenic epithelial tumor, characterized by slow growth and local invasiveness [1,2]. According to the latest WHO system, AB is classified into AB, unicystic, and extraosseous/peripheral types [3]. Among them, AB is the most common type, but its etiology and pathogenesis remain to be clarified [4]. Most patients are treated by surgical resection. However, surgical removal often results in facial deformities, and patients undergoing conservative treatment often have relapse [5]. Targeted therapy may be a promising treatment for AB and effective therapeutic targets need to be explored.

Abnormal gene expression can participate in the development of AB. NCAM1 is a cell adhesion family molecule in the immunoglobulin molecule superfamily [6]. It is mainly expressed in the nervous system and is involved in regulating the function of nerve cells and neuronal migration [7]. In human hematopoietic, NCAM1 is expressed in NK cells, rare subsets of T and B lymphocytes, dendritic cells, and neural or mesenchymal stem cells [8–11]. NCAM1 is the best surface antigen for identification of human NK cells [12,13]. Furthermore, NCAM1 is widely expressed during embryogenesis [8]. Recent findings have suggested that abnormally expressed NCAM1 is associated with development of various cancers, such as acute myeloid leukemia [11], small-cell lung cancer [14], and breast cancer [15]. Its dysregulation can be regulated by several factors and has been confirmed as a target of miR-572 in human oligodendrogial cells [16]. Thus, in this study, the expression and function of NCAM1 in AB were analyzed.

MicroRNAs (miRNAs) are endogenous non-coding RNAs about 20–24 nucleotides in size [17]. miRNAs can silence their target genes at post-transcriptional levels [18]. Numerous studies have reported that miRNAs mediate a variety of tumors, including AB [19]. Among them, miR-141-3p can modulate cell migration and invasion in several cancers through silencing downstream targets. For example, low miR-141-3p expression induces prostate cancer bone metastasis through activation of the NF-κB pathway [20]. miR-141-3p suppresses colorectal cancer cell invasion via targeting TRAF5 [21] and can promote invasion and tumorigenesis of cervical cancer cells via inhibiting FOXA2 [22]. Intriguingly, local invasion is one of the main characteristics of AB. E-cadherin, a cell adhesion molecule, is mainly expressed on the membrane of epithelial cells. Increasing evidence shows that abnormal expression of E-cadherin is related to the aggressive behavior of AB [23]. However, the expression and potential molecular mechanisms of miR-141-3p in AB remain to be explored.

In this study, we hypothesized that highly expressed NCAM1 can suppress the migration behavior of AB, and that its expression is regulated by miR-141-3p.
DAB kit, the sections were rinsed, counterstained, dehydrated, cleared, and sealed. In the negative control group, PBS was used instead of the primary antibody. The semiquantitative scores were assessed based on staining intensity and the percentage of positive cells. Three fields of vision were selected for scoring at 200 magnification and the scores were averaged. The scoring criteria were: strong positive (4 points), positive (3 points), weak positive (2 points), and negative (1 point).

Dual luciferase reporter assay

The 3’-UTR of NCAM1 containing predicted miR-141-3p binding sites was constructed into the pmirGLO vector (Gene Pharma, China). Then, 293T cells were cultured in 24-well plates and co-transfected with WT (wild-type) or MUT (mutant) and miR-141-3p mimics or miR-NC mimics, respectively. The relative luciferase activities were measured using the Dual Luciferase Reporter Assay System.

Cell culture and transfection

The human ameloblastoma cell line AM-1 was cultured in keratinocyte serum-free medium (KSFM) and incubated at 37°C and 5% CO₂. Then, AM-1 cells were seeded into 12-well plates containing 1 ml of KSFM medium per well until the degree of cell fusion reached approximately 80%. For cell transfection, miR-141-3p mimics, NCAM1 overexpression, and their corresponding NCs were transfected into AM-1 cells.

Wound-healing assay

A horizontal line was drawn evenly on the back of the 6-well plates. Transfected cells were then seeded in 6-well plates. Next, the pipette tip was used to scrape the cell-covered surface, making sure that the scrape was perpendicular to the horizontal line. Scratch photos were taken at 0 h and 24 h, and the area and length of each scratch photo were measured using ImageJ software.

Statistical analysis

All statistical data were analyzed using Graphpad Prism 8.0 and SPSS 23.0. Data are expressed as mean±standard deviation (SD) from at least 3 times repeated experiments. The t test was performed to compare differences between the 2 groups. Correlations between NCAM1 and clinicopathological factors were analyzed by one-way chi-square analysis. P<0.05 was considered statistically significant.

Results

miR-141-3p was significantly downregulated in AB tissues

Our previous microarray analysis revealed that miR-141-3p was differentially expressed between AB and NOM tissues. The expression level of miR-141-3p between AB and NOM tissues was verified using real-time qPCR. The results showed that its expression was 12.5 times lower in AB than that in NOM (P<0.001; Figure 1).

NCAM1 was significantly upregulated in AB tissues

We assessed and compared the expression levels of NCAM1 between 13 AB tissues and 7 NOM tissues via real-time qPCR. The results suggested that its expression was 4.7 times higher than that in NOM tissues.

Table 1. The clinical feature information of patients with AB.

| Clinicopathological characteristics | Number of case (n=96), % |
|------------------------------------|-------------------------|
| Age (years)                        |                         |
| <50                                | 70 (72.92)              |
| ≥50                                | 26 (27.08)              |
| Gender                             |                         |
| Male                               | 54 (56.25)              |
| Female                             | 42 (43.75)              |
| Location                           |                         |
| Maxilla                            | 18 (18.75)              |
| Mandible                           | 78 (81.25)              |
| Pathological type                  |                         |
| AB                                 | 96 (100.00)             |
| Others                             | 0 (0.00)                |
| Recurrence                         |                         |
| Yes                                | 9 (9.38)                |
| No                                 | 87 (90.62)              |

Table 2. The primer sequences for real-time qPCR.

| Target   | Primer sequences                      |
|----------|---------------------------------------|
| miR-141-3p | 5’-AGCCGCTAACCCTGTCTCTGTA-3’ (forward) |
|          | 5’-CAGACAGGCTCGAGGTA-3’ (reverse)     |
| U6       | 5’-ATGGAAAGTACAGAAGAT-3’ (forward)    |
|          | 5’-GGGCAATGTTAATTTTCTTG-3’ (reverse)  |
| NCAM1    | 5’-AATTACGGCCGGAAGAAT-3’ (forward)    |
|          | 5’-CCTGGCTGGGAAATATCC-3’ (reverse)   |
| β-actin  | 5’-CTCATCGTCGCTGCTGTT-3’ (forward)    |
|          | 5’-GCTTGTCACCTTACCCGT-3’ (reverse)   |
Moreover, we found that NCAM1 had a higher expression level in AB tissues compared to NOM tissues at the protein level (P<0.05; Figure 3A, 3B).

Expression and distribution of NCAM1 and E-cadherin in AB tissues

As shown in immunohistochemistry results, NCAM1 was mainly expressed in the cell membrane of AB. Figure 4A shows ameloblast follicles containing pre-ameloblast-like cells and a central core of loosely arranged stellate reticulum-like cells supported by loose fibrous stroma. NCAM1 was strongly positively expressed in the plasma membrane of ameloblast-like cells and partial stellate reticulum-like cells of follicular AB. However, it was negatively expressed in interstitial collagen fibroblasts. As shown in Figure 4B, tumor epithelial cell proliferation was a network-connected epithelial cord, with central cells surrounded by surrounding cells resembling stellate reticulocytes. NCAM1 was moderately positively expressed in the plasma membrane of peripheral and stellate reticulum in plexiform AB. It is well-established that E-cadherin is associated with tumor invasiveness. Thus, we assessed the expression and distribution of E-cadherin in AB. As shown Figure 4C, we found that E-cadherin was positively expressed in the plasma membrane of the peripheral layer of follicular AB and was weakly positively expressed in the stellate reticulum cells, but it was not expressed in interstitial fibroblasts. In addition, higher NCAM1 expression in AB was found than that in NOM (P<0.001; Table 3). However, the expression of NCAM1 was not significantly correlated with sex, age, recurrence, location, or lesion type of patients with AB (Table 3).

NCAM1 was regulated by miR-141-3p

As predicted by bioinformatics analysis results, there was a binding site between miR-141-3p and NCAM1 by the TargetScan database. To validate their relationship, a luciferase reporter plasmid containing NCAM1-WT and NCAM1-MUT of the miR-141-3p binding site was constructed (p<0.05, Figure 5A). NCAM1-WT or NCAM1-MUT luciferase reporter plasmid and miR-141-3p mimics or miR-141-3p NC were co-transfected in 293T cells and assayed for luciferase activity. As displayed in Figure 5B, the relative luciferase activity of NCAM1-WT was significantly decreased, while the relative luciferase activity of the NCAM1-MUT was unchanged. These results suggested that NCAM1 was a target of miR-141-3p.

miR-141-3p mimics were used to overexpress miR-141-3p in AM-1 cells. As shown in Figure 6A, miR-141-3p was successfully downregulated in AB tissues compared to NOM tissues. *** p<0.001.

miR-141-3p was successfully upregulated in AB tissues compared to NOM tissues according to real-time qPCR results. * p<0.05.

in AB than in NOM at the mRNA level (P<0.05; Figure 2). Moreover, we found that NCAM1 had a higher expression level in AB tissues compared to NOM tissues at the protein level (P<0.05; Figure 3A, 3B).
Figure 4. Immunohistochemistry results showing the expression and distribution of NCAM1 and E-cadherin in AB. Positive NCAM1 expression in follicular AB (A) and plexiform AB (B); (C) Positive E-cadherin expression in follicular AB. Magnification, ×200; scale bar=100 μm. Black arrows represents positive expression and red arrows represents negative expression.

Table 3. Correlation between NCAM1 expression and clinicopathological factors of patients with AB.

| Clinicopathological factors | Groups   | Number of cases | NCAM1 positive expression rate, % | $\chi^2$ | P value |
|-----------------------------|----------|-----------------|-----------------------------------|---------|---------|
| Age                         |          |                 |                                   |         |         |
|                            | >50      | 26              | 80.77                             | 0.07    | 0.93    |
|                            | ≤50      | 70              | 80.00                             |         |         |
| Gender                      |          |                 |                                   |         |         |
|                            | Male     | 54              | 77.78                             | 0.46    | 0.50    |
|                            | Female   | 42              | 83.33                             |         |         |
| Location                    |          |                 |                                   |         |         |
|                            | Mandible | 78              | 79.49                             | 0.14    | 0.71    |
|                            | Maxillary| 18              | 83.33                             |         |         |
| Type                        |          |                 |                                   |         |         |
|                            | Solid    | 71              | 80.28                             | 0.001   | 0.98    |
|                            | Peripheral/desmoplastic | 25  | 80.00                             |         |         |
| Recurrence                  |          |                 |                                   |         |         |
|                            | Yes      | 9               | 77.78                             | 0.04    | 0.85    |
|                            | No       | 87              | 80.46                             |         |         |
| Total positive rate         |          |                 |                                   | 29.32   | <0.001  |
overexpressed (P<0.05). The expression of NCAM1 was significantly inhibited in AM-1 cells after miR-141-3p overexpression (P<0.05, Figure 6B).

**NCAM1 inhibits AM-1 cell migration**

We further observed whether NCAM1 could affect the migration of AB cells. Firstly, RT-qPCR results confirmed that NCAM1 was successfully overexpressed in AM-1 cells (p<0.001, Figure 7A). After that, the cell scratch test was performed. We found that the migration ability of AM-1 cells was significantly inhibited after NCAM1 overexpression (P<0.05, Figure 7B, 7C). These results suggest that NCAM1 inhibits AM-1 cell migration.

**Discussion**

The etiology and pathogenesis of AB remain to be clarified. In this study, highly expressed NCAM1 was found in AB tissues and it could inhibit migration of AB cells. Furthermore, it was regulated by miR-141-3p in AB cells. Our findings present novel insights into the mechanism of AB.

Tumor formation involves cell adhesions and interaction with surrounding cells and extracellular matrix [24]. Abnormal adhesion may be a determinant of epithelial tumor formation [25,26]. Thus, we observed the effect of adhesion molecule NCAM1 on the biological behavior of AB. The reduction of cell adhesion is closely related to tumor metastasis [27]. For example, the abnormal expression of the cell adhesion molecule CD44 and its variants is related to cell invasion and metastatic potential of various cancers [28–30]. Highly expressed NCAM1 was found in AB tissues at the mRNA and protein levels in our study. Its high expression significantly suppressed the migration and invasion of AB cells. Consistent with previous studies, NCAM1 appears to be involved in the aggressiveness of tumor cells, but not AB. For example, dysregulated NCAM1 is related to the invasiveness ability of human skin squamous cell carcinoma cells [31]. We found that NCAM1 was mainly expressed on the cell membrane of AB. Consistent with Western blot results, immunohistochemistry results confirmed that NCAM1 was highly expressed in AB, but there was not a significant correlation between its expression and clinical features. Our results suggest that NCAM1 is involved in migration and invasion of AB cells.

Studies have found that signaling pathways related to odontogenesis can promote the pathogenesis of AB [2]. Epithelial-mesenchymal transition (EMT) has been reported to activate early dentinogenesis and promote AB development [32]. EMT serves as an early-stage factor for malignant transformation.

**Figure 5.** Luciferase reporter assay. Dual luciferase confirmed miR-141-3p and NCAM1 interaction in AM-1 cells (A, B). * p<0.05; ns indicated no statistical significance.

**Figure 6.** NCAM1 is regulated by miR-141-3p. (A) Transfection effect of miR-141-3p mimics and inhibitors in AM-1 cell was detected by real-time qPCR. (B) Real-time qPCR showed that NCAM1 was significantly inhibited in AM-1 cells transfected with miR-141-3p mimics. * p<0.05.
of tumor epithelial cells. Epithelial marker E-cadherin expression loss occurs during EMT, which is closely related to the invasion and metastasis of AB [33]. Consistent with previous studies, we found that E-cadherin was mainly expressed on the cell membrane of AB, indicating the invasive behavior of AB cells [2,33].

In our study, low expression of miR-141-3p was observed in AB tissues. Its low expression has been found in several cancers and is related to cell migration and invasion in colorectal cancer [21], pancreatic cancer [34], cervical cancer [22], and papillary thyroid cancer [35]. Based on the evidence presented above, we speculate that miR-141-3p is involved in migration and invasion of AB cells by targeting NCAM1. Dual luciferase reporter assay confirmed that NCAM1 was a target of miR-141-3p in AM-1 cells. Furthermore, miR-141-3p overexpression significantly inhibited the expression NCAM1 in AM-1 cells. These results suggest that miR-141-3p participates in the development of AB by inhibiting NCAM1.

Figure 7. NCAM1 inhibits AM-1 cell migration. (A) Validation of the transfection effects of NCAM1 overexpression in AM-1 cells. (B, C) The inhibitory effect of NCAM1 overexpression on the migration behavior of AM-1 cells, as shown in wound-healing assay results. * p<0.05; *** p<0.001.
Conclusions

NCAM1 was significantly overexpressed in AB tissues, and its dysregulation inhibited the invasive behavior of AB. Furthermore, we found that NCAM1 expression was regulated by miR-141-3p, which could be a potential therapeutic target for AB.

References:

1. Nakano K, Takabatake K, Kawai H et al: Notch signaling affects oral neo- plasm cell differentiation and acquisition of tumor-specific characteristics. Int J Mol Sci, 2016; 17(3): pii: E9173
2. Zhang J, Wang Y, Fan C et al: Interleukin-1R-beta-catenin mediates epithelial-mesenchymal transition in ameloblastoma. Oral Dis, 2019, 25(8): 1964–71
3. Wright JM, Vered M: Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and maxillofacial bone tumors. Head Neck Pathol, 2017; 11(1): 68–77
4. Okada T, Fujitsu K, Ichikawa T et al: Unicystic ameloblastomatoid cystic cranio-angiomyxoma: pathological discussion and clinical significance of cyst formation in adamantinomatous cranioangiomyxoma. Padiat Neurosurg, 2016; 51(3): 158–63
5. Kurppa KJ, Catón J, Morgan PR et al: High frequency of BRAF V600E mutations in ameloblastoma. J Pathol, 2014; 232(5): 492–98
6. Siles AM, Martínez-Hernández E, Arapek J et al: Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuroepithalopathies. Ann Clin Transl Neurol, 2018; 5(5): 559–69
7. Gu MI, Ha JO: CD56 positive diffuse large B-cell lymphoma: A case report and literature review. Int J Clin Exp Pathol, 2013; 6(12): 3023–25
8. Chen L, Youssy F, Robinson C et al: CD56 expression marks human group 2 innate lymphoid cell divergence from a shared NK cell and group 3 innate lymphoid cell developmental pathway. Immunity, 2018; 49(3): 464–76.e4
9. Crossland DL, Denning WL, Ang S et al: Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 2018; 37(27): 3866–97
10. Huang L, Liu D, Wang N et al: Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res, 2018; 28(2): 172–86
11. Sasca D, Szybinski J, Schüler A et al: NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood, 2019; 131(21): 2305–19
12. Voigt J, Malone DFG, Dias J et al: Proteome analysis of human CD56(neg) NK cells reveals a homogeneous phenotype surprisingly similar to CD56(dim) NK cells. Eur J Immunol, 2018; 48(9): 1456–69
13. Wagner JA, Rosario M, Romee R et al: CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest, 2017; 127(12): 4042–58
14. Weiskopf K, Jahchan NS, Schnorr PJ et al: CD47-blocking immunotherapies are a novel target for AB. Mol Cancer, 2018; 17(3): pii: e921863
15. Ghaderi F, Ahmadvand S, Ramezani A et al: Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochem Biophys Res Commun, 2018; 505(1): 181–86
16. Bhattacharya R, Mitra T, Ray Chaudhuri S, Roy SS: Mesenchymal splice iso- form of CD44 (CD44s) promotes EMR/invasivity and imparts stem-like proper- ties to ovarian cancer cells. J Cell Biochem, 2018; 119(4): 3373–83
17. Mueller N, Winklein D, Eisenwort G et al: CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocyto- sis. Blood, 2018; 132(18): 1936–50
18. Yang Z, Qin W, Chen Y et al: Cholesterol inhibits hepatocellular carcino- ma invasion and metastasis by promoting CD44 localization in lipid rafts. Cancer Lett, 2018; 429: 66–77
19. Chen L, Wang G, Qiao X et al: Downregulated miR-524-5p participates in the tumor microenvironment of ameloblastoma by targeting the Interleukin-33 (IL-33)/suppression of tumorigenicity 2 (ST2) axis. Med Sci Monit, 2020; 26: e921863
20. Huang S, Wu Q, Pan J et al: Downregulation of miR-141-3p promotes bone metastasis via activating NF-kappaB signaling in prostate cancer. J Exp Clin Cancer Res, 2017; 36(1): 173
21. Li J, Xu L, Liu S et al: MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys Res Commun, 2019; 514(3): 699–705
22. Li JH, Zhang Z, Du NZ et al: microRNA-141-3p fosters the growth, inva- sion, and tumorigenesis of cervical cancer cells by targeting FOXA2. Arch Biochem Biophys, 2018; 657: 23–30
23. Kurioka K, Wato M, Iseki T et al: Differential expression of the epithelial mesenchymal transition factors Snail, Slug, Twist, TGF-beta, and E-cadherin in ameloblastoma. Med Mol Morphol, 2017; 50(2): 68–75
24. Fried P, Alexander S: Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell, 2011; 147(5): 992–1009
25. Lee J, Chu BH, Sen S et al: Modulating malignant epithelial tumor cell adhe- sion, migration and mechanics with nanorod surfaces. Biomed Microdevices, 2011; 13(1): 89–95
26. Sokeland G, Schumacher U: The functional role of integrins during intra- and extravasation within the metastatic cascade. Mol Cancer, 2019; 18(1): 12
27. Hamidi H, Ivaska J: Every step of the way: Integrins in cancer progression and metastasis. Nat Rev Cancer, 2018; 18(9): 533–48
28. Bhattacharyya R, Mitra T, Ray Chaudhuri S, Roy SS: Mesenchymal splice iso- form of CD44 (CD44s) promotes EMR/invasivity and imparts stem-like proper- ties to ovarian cancer cells. J Cell Biochem, 2018; 119(4): 3373–83
29. Mueller N, Winklein D, Eisenwort G et al: CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocyto- sis. Blood, 2018; 132(18): 1936–50
30. Yang Z, Qin W, Chen Y et al: Cholesterol inhibits hepatocellular carcino- ma invasion and metastasis by promoting CD44 localization in lipid rafts. Cancer Lett, 2018; 429: 66–77
31. Brugiere C, El Bouchtaoui M, Leboeuf C et al: Perineural invasion in human cutaneous squamous cell carcinoma is linked to neurotrophins, epitheli- al-mesenchymal transition, and NCAM1. J Invest Dermatol, 2018; 138(9): 2063–66
32. Siar CH, Ng KH: Epithelial-to-mesenchymal transition in ameloblastoma: Focus on morphologically evident mesenchymal phenotypic transition. Pathology, 2019; 51(5): 494–501
33. Carreón-Burciaga RG, González-González R, Molina-Frechero N et al: Differences in E-cadherin and syndecan-1 expression in different types of ameloblastomas. Anal Cell Pathol (Amst), 2018; 23: 9392632
34. Carreón-Burciaga RG, González-González R, Molina-Frechero N et al: Differences in E-cadherin and syndecan-1 expression in different types of ameloblastomas. Anal Cell Pathol (Amst), 2018; 23: 9392632
35. Fang M, Huang W, Wu X et al: MiR-141-3p suppresses tumor growth and invasion in papillary thyroid cancer via targeting Yin Yang 1. Anat Rec (Hoboken), 2019; 302(3): 258–68

Conflicts of interest
None.